Bio-Techne Corp (TECH) exhibits 64.8% gross margins and 3.4% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 91.3x enterprise multiple and 4.8% implied options volatility.
Sustained 64.8% gross profitability converts into 8.4% operating margin and 3.4% ROIC, outpacing sector cost of capital.
ROIC: 3.4% // GM: 64.8%YoY revenue trajectory of +5.2% paired with 2.25% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.2% // FCF YLD: 2.25%Altman Z-Score of 7.12 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 7.12 // F-SCORE: 8/9Trading at 155.3x trailing P/E (140.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 155.3x // EV/EBITDA: 91.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $72.66 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 6.0% net margins.
NET MARGIN: 6.0% // D/E: 0.25x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TECH & activate live FRED threshold breach alerts.